Exogenous antigens are mainly presented to major histocompatibility complex (MHC) class II molecules, but are also presented to MHC class I molecules via the antigen cross-presentation process in dendritic cells. The enhancement of cross-presentation of an injected vaccine antigen by an adjuvant ...
Evaluation of vaccine effectiveness of mRNA COVID-19 vaccines in children: a systematic review and meta-analysis OBJECTIVE: To evaluate the vaccine effectiveness (VE) of mRNA COVID-19 vaccines in children using a meta-analysis approach. MATERIALS AND METHODS: Relevant... Y.-H. Hu,Y. Ding,L...
We tested this new vaccine in vivo in a mouse model of peritonitis against the standard strain ATCC 19606 in addition to 3 clinical isolates of A. baumannii. Immunization with this vaccine completely protected the challenged mice with 100% survival rate in the case of all the tested bacteria....
This discovery is a first step to the development of a diagnostic test system and a vaccine to detect and fight this life‐threatening pathogen. Details are discussed in the Full Paper by N. E. Nifantiev et al. on p. 1029 ff.
The need for multiple vaccinations to enhance the immunogenicity of subunit vaccines may be reduced by delivering the vaccine over an extended period of time. Here, we report two novel injectable pentablock copolymer based thermoresponsive hydrogels made of polyethyleneglycol-polycaprolactone- polylactide-...
This case-study highlights the analytical and formulation challenges encountered with three recombinant non-replicating rotavirus vaccine (NRRV) antigens (t-NRRV formulated with Alhydrogel(R) adjuvant, AH) combined with a mock multidose formulation of a pediatric pentavalent vaccine used in LMICs. ...
A vaccine containing one or more of the peptides and a carrier is also claimed. USE/ADVANTAGE - B19 virus causes infection associated with erythema infectiosum. After developing erythema infectiosum (fifth disease), antibodies to B19 are found in the blood. B19 appears to be associated with ...
Introduction: PENTAXIMTM (Sanofi), DTaP- IPV//Hib, a pentavalent combination vaccine for protection against diphtheria, tetanus, per- tussis, poliomyelitis, and invasive infections caused by Haemophilus influenzae type b, has been licensed in South Korea by the Ministry of Food and Drug Safety (...